Do Patien
t-Reporte
NOW AVAILABLE...
The ASH Clinical News
iPad App!
The latest news and views for the broader
hematology/oncology community, now
delivered to your iPad.
d Outcom
r? ... p. 32
Your so
urc
perspec e for worldwid
tives on
e
hematol news and
ogy/onc
ology
01 | num
ber 02
CONTE
N
TS
4… Editor
volume
's Corne
r
A Letter
to the AB
IM
8… Pulling
Bac
Benjam k the Curtain
in Ebert
on
Juggling
Work an
d Family
14… He
matol
The Endoogy Link
Perspec crinologist’s
tive on Di
Managem
abetes
ent
25… On
februar
y 2015
Locatio
n
Highlight
Annual s from the ASH
Meeting
31… Bes
t Practic
es
Choosin
g
the Inte Wisely Across
rn
Spectru al Medicine
m
34… PAS
Hions
Hagop Ka
ntarjian’s
“Beirut”
DEPART
MENTS
5 UP FRO
NT
16 CLINIC
AL NEW
S
28 TRA
INING AN
D EDUCAT
32 FEA
ION
TURES
34 BAC
K OF THE
BOOK
www.ASH
ClinicalN
ews.org
MOC Mea C
ulpa
Is the AB
IM's ap
too little
, too lateology
?
Latest & Gre
Drug and Devatest:
News ... 15 ice
Table 7: Percent Incidence of Clinically Relevant Grade 3/4* Laboratory
Abnormalities
Patient Population
Resistant or
Intolerant Ph+
Newly Diagnosed
Ph+ CML-CP
CML-CP
CML-AP
TASIGNA Imatinib
TASIGNA TASIGNA
300 mg
400 mg
400 mg
400 mg
twice-daily once-daily twice-daily twice-daily
N=279
N=280
N=321
N=137
(%)
(%)
(%)
(%)
Biochemistry Parameters
Elevated creatinine
0
<1
<1
<1
*NCI Common Terminology Criteria for Adverse Events, version 3.0
1CML-CP: Thrombocytopenia: 12% were grade 3, 18% were grade 4
2CML-CP: Neutropenia: 16% were grade 3, 15% were grade 4
3CML-AP: Thrombocytopenia: 11% were grade 3, 32% were grade 4
4CML-AP: Neutropenia: 16% were grade 3, 26% were grade 4
Elevated total cholesterol (all grades) occurred in 28% (Tasigna 300 mg bid)
and 4% (imatinib). Elevated triglycerides (all grades) occurred in 12% and
8% of patients in the Tasigna and imatinib arms, respectively. Hyperglycemia
(all grades) occurred in 50% and 31% of patients in the Tasigna and imatinib
arms, respectively.
Most common biochemistry laboratory abnormalities (all grades) were alanine aminotransferase increased (72%), blood bilirubin increased (59%),
aspartate aminotransferase increased (47%), lipase increased (28%), blood
glucose increased (50%), blood cholesterol increased (28%), and blood
triglyceride increased (12%).
6.2 Additional Data from Clinical Trials
The following adverse drug reactions were reported in patients in the
Tasigna clinical studies at the recommended doses. These adverse drug
reactions are ranked under a heading of frequency, the most frequent
first using the following convention: common (≥1% and <10%), uncommon (≥0.1% and <1%), and unknown frequency (single events). For laboratory abnormalities, very common even